RS BIOTHERAPEUTICS
OperatingRS Bio Therapeutics, Inc.
Biotech · Biotech · Cumberland, MD · Founded 2021
Novel solutions for lung diseases
Financials
FY2021–FY2025 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Valuation caps on SAFE / convertible note roundsDashed amber bars are a SAFE or convertible note's valuation cap — the most it converts at, not what the company is worth.
Share price over rounds
Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines.
Cap table
Principal holders% as the filing states it, Sep 23, 2026
- Justin Molignoni34.0%of company
- Dustin Freas29.0%of company
- William Freas24.0%of company
Sold to the crowd
- Reg CF · May 2024Series Seed-1 Preferred Stock$195.2K· 90 investors
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
7 people
Possessing over 40 years of broad biopharmaceutical experience including roles of increasing responsibility at Bristol-Myers Squibb, Eisai, Takeda, AcelRx, and Adamas, Dean has built and led organizations for two multi-billion dollar pharmaceutical brands. Dean earned a MBA from the Kellogg School of Management at Northwestern University.
A finance leader with extensive experience across all financial disciplines. Curtis’ pharmaceutical experience includes VP Finance of Takeda Pharmaceuticals where he led all financial functions of a $3.5 billion business and CFO of Ovation Pharmaceuticals. A CPA, Curtis earned his Bachelors in Business Administration from Texas A&M University.
Recognized in 2019 as one of the Top 100 Healthcare Leaders by the International Forum on Advancements in Healthcare, Justin’s research has been presented at the Institute for Healthcare Improvement and published by the Society of Critical Care Medicine. Justin earned a Master of Science Nurse Practitioner from Simmons Collins Graduate Studies.
With 25+ years’ experience across health-related industries, Michelle began her pharma career at Boehringer Ingelheim, focusing on COPD and launching a blockbuster brand. Other leadership roles encompass medical education initiatives, strategy, and cannabinoid science. Following medical school at University of Kentucky, she completed residency at UCLA.
Possesses over two decades of healthcare expertise. As CEO of Novus Pain Management, Dustin focuses on pain management and opioid reduction for seniors. Dustin spearheaded workforce expansion at Flagship Rehabilitation to over 400 employees while introducing key recruitment and retention strategies. Dustin earned a Masters Healthcare Systems from Duquesne University.
Names and titles as disclosed on SEC Form C, StartEngine. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 2 of 2 annual reports (FY2024–FY2025)
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 11 filings on EDGAR- Form C-ARSep 23, 20260001932193-26-000004EDGAR
- Form C-TRSep 23, 20260001932193-26-000005EDGAR
- Form C-ARMay 2, 20250001665160-25-000955EDGAR
- Form DOct 9, 20240001932193-24-000001EDGAR
- Form C-USep 6, 20240001665160-24-001291EDGAR
- Form C/AMay 22, 20240001665160-24-000900EDGAR
- Form CApr 29, 20240001665160-24-000649EDGAR
- Form D/AOct 19, 20230001932193-23-000003EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.